Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer

Annals of Oncology

Volumn 23, Issue 1, 2012, Pages 93-97

  Olson, E M ^a   Lin, N U ^a   Dipiro, P J ^a   Najita, J S ^a   Krop, I E ^a   Winer, E P ^a   Burstein, H J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

HER2 neu; Lapatinib; Metastatic breast cancer; Trastuzumab; Trastuzumab DM1

Indexed keywords

BEVACIZUMAB; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PACLITAXEL; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; FEMALE; HUMAN; METASTASIS POTENTIAL; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GENES, ERBB-2; HUMANS; KAPLAN-MEIER ESTIMATE; MAYTANSINE; MIDDLE AGED; NEOPLASM STAGING; QUINAZOLINES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84855176565     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr061     Document Type: Article

References (12)

1. Hudis C. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51.
2. Isakoff SJ, Baselga J. Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2011; 29(4): 351-354.
3. Baselga J. Treatment of HER2-overexpressing breast cancer. Ann Oncol 2010; 21 (Suppl 7): vii36-vii40.
4. Krop IE, Beeram M, Modi S et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010; 28: 2698-2704.
5. Burris HA, Rugo HS, Vukelja SJ et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011; 29(4): 398-405.
6. Krop I, LoRusso P, Miller K et al. A phase II study of trastuzumab-DM1 (T-DM1), a novel HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer who were previously treated with an anthracycline, a taxane, capecitabine, lapatinib, and trastuzumab. In European Society for Medical Oncology (Abstr 2770). Milan, Italy 2010.
7. von Minckwitz G, du Bois A, Schmidt M et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03-05 study. J Clin Oncol 2009; 27: 1999-2006.
8. Blackwell KL, Burstein HJ, Storniolo AM et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010; 28: 1124-1130.
9. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743.
10. Burstein HJ, Sun Y, Dirix LY et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2010; 28: 1301-1307.
11. Baselga J, Cortes J, Fumoleau P et al. Pertuzumab and trastuzumab: reresponses to 2 biological agents in patients with HER2-positive breast cancer which had previously progressed during therapy with each agent given separately: a new biological and clinical observation. In San Antonio Breast Conference Series (Abstr 5114). San Antonio, TX 2009.
12. Spazzapan S, Crivellari D, TumoloV S, Russo A. Retreatment with trastuzumab after progression on lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a monoinstitutional experience. In American Society of Clinical Oncology (Abstr 1082). Chicago, IL 2010.